Prospective Activity of PLG0206, an Engineered Antimicrobial Peptide, on Chronic Periprosthetic Joint Infection Total Knee Arthroplasty Components <i>Ex Vivo</i> : The Knee Explant Analysis (KnEA) Study

  • David Huang
    Peptilogics, Pittsburgh, Pennsylvania, USA
  • Dana M. Parker
    Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  • Jonathan B. Mandell
    Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  • Kimberly M. Brothers
    Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  • Charles G. Gish
    Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  • John A. Koch
    Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  • Nicholas Pachuda
    Peptilogics, Pittsburgh, Pennsylvania, USA
  • Despina Dobbins
    Peptilogics, Pittsburgh, Pennsylvania, USA
  • Jonathan Steckbeck
    Peptilogics, Pittsburgh, Pennsylvania, USA
  • Kenneth L. Urish
    Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

抄録

<jats:p> Chronically infected prosthetics of the knee were exposed to PLG0206, an engineered antimicrobial peptide, at a concentration of 1 mg/mL for 15 min. Consequently, a mean 4-log <jats:sub>10</jats:sub> reduction (range, 1 to 7) in the number of bacteria occurred, which may translate to improved clinical outcomes for persons with prosthetic joint infection of the knee. </jats:p>

収録刊行物

  • Microbiology Spectrum

    Microbiology Spectrum 9 (3), e0187921-, 2021-12-22

    American Society for Microbiology

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ